StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead Sciences (GILD) Reimbursement Experts Confirm HIV Market Opportunity is Well Insulated - RBC Capital
June 3, 2020 6:29 AM
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $88.00 price target on Gilead Sciences (NASDAQ: GILD) after discussions ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Gilead Sciences (GILD), Galapagos NV (GLPG) Report Filgotinib Demonstrates Durable Efficacy & Consistent Safety Profile at 52-Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
June 4, 2020 6:09 AM